We are thrilled to announce the publication of our groundbreaking work in PLoS Computational Biology, introducing PESSA (Pathway Enrichment Score-based Survival Analysis) – a robust, user-friendly web platform designed to revolutionize cancer survival data analysis. PESSA uniquely integrates pathway enrichment status as a critical biomarker, offering oncologists and researchers unprecedented insights. Our platform boasts an expansive curated database of over 200 cancer datasets from leading sources (GEO, TCGA, EGA, and published literature), encompassing 51 cancer types, 13 distinct survival outcome measures, and over 13,000 tumor-relevant pathways. PESSA is meticulously designed to accelerate the discovery and validation of novel cancer-related pathway biomarkers. Access PESSA today at: https://smuonco.shinyapps.io/PESSA/ or http://robinl-lab.com/PESSA.

When a cheeseburger costs less than a punnet of strawberries, it’s clear the odds are stacked against healthy choices – especially for teenagers. Now, new research from the University of South Australia shows that it’s not just unhealthy eating habits affecting teens, but an alarming clustering of poor lifestyle choices that’s putting the majority of teenagers at serious risk of preventable diseases later in life.

In a paper published in MedComm – Future Medicine, a Chinese research team presents ImmunoCheckDB, a comprehensive web platform integrating meta-analysis and multiomic data to discover cancer immunotherapy biomarkers. The platform curates 173 studies on immune checkpoint inhibitor (ICI) therapies, covering survival outcomes for 93,234 individuals across 18 cancer types and 30 ICI regimens, enabling pan-cancer exploration of molecular markers for ICI efficacy.

A comprehensive review finds that GLP-1 receptor agonists, popular diabetes medications, show varying effects on cancer risk - protective against some cancers while potentially increasing risk for others. The findings emphasize the need for personalized treatment approaches.